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Fragile X and X-Linked Intellectual Disability:
Four Decades of Discovery
Herbert A. Lubs,1 Roger E. Stevenson,1,* and Charles E. Schwartz1X-Linked intellectual disability (XLID) accounts for 5%–10% of
intellectual disability in males. Over 150 syndromes, the most
common of which is the fragile X syndrome, have been described.
A large number of families with nonsyndromal XLID, 95 of which
have been regionally mapped, have been described as well. Muta-
tions in 102 X-linked genes have been associated with 81 of these
XLID syndromes and with 35 of the regionally mapped families
with nonsyndromal XLID. Identification of these genes has
enabled considerable reclassification and better understanding of
the biological basis of XLID. At the same time, it has improved
the clinical diagnosis of XLID and allowed for carrier detection
and prevention strategies through gamete donation, prenatal
diagnosis, and genetic counseling. Progress in delineating XLID
has far outpaced the efforts to understand the genetic basis for
autosomal intellectual disability. In large measure, this has been
because of the relative ease of identifying families with XLID
and finding the responsible mutations, as well as the determined
and interactive efforts of a small group of researchers worldwide.
Introduction
Mutations resulting in X-linked intellectual disability
(XLID) have been described in 102 genes (Table S1, avail-
able online).1 This work was accomplished over a 40 year
period during which the term X-linked mental retardation
was widely used; however, we will use intellectual
disability (ID), which is emerging as the preferred termi-
nology. Mutations in these 102 genes are responsible for
81 of the known 160 XLID syndromes and over 50 families
with nonsyndromal XLID (Table S1 and Figures 1 and 2).
An additional 30 XLID syndromes and 48 families with
nonsyndromal XLID have been regionally mapped (Table
1 and Figures 2 and 3), but the genes not yet identified.
Forty-four XLID syndromes, which remain unmapped,
have also been described (Table S2). Fewer than 400 auto-
somal genes in which mutations resulted in ID have
been identified. Of 1,640 references to ID in OMIM (as of
March 2010), 316 are entities on the X chromosome. Three
comparably sized chromosomes (6, 7, and 8) show 50, 58,
and 60 references, respectively. Several authors have
recently discussed the possibility that these striking differ-
ences might result from a relative concentration of genes
that influence intelligence on the X chromosome.2,3
Identification of the mutations in 102 genes that cause
XLID has been accomplished primarily through long-
term, planned and coordinated studies from the United
States, Europe, and Australia. These studies took advantage
of the power of pedigrees of relatively large families to1Greenwood Genetic Center, JC Self Research Institute of Human Genetics, 11
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The Amassign putative genes to the X chromosome, linkage anal-
ysis to achieve regional localizations, accumulation and
sharing of large data banks of clinical details and speci-
mens, registries of pertinent X chromosomal transloca-
tions and abnormalities, stored samples from a variety of
populations around the world with ID and effective
communication between numerous investigators. In this
setting, the continuously developing technologies were
applied and reapplied to the available clinical and spec-
imen banks effectively and rapidly. A comparable system-
atic approach to autosomal ID has not been carried out.
Publication of the first family with the marker X,4 later
renamed the fragile X (MIM 300624),5 gave an important
impetus to the field by providing a laboratory tool
which clearly identified the most prevalent XLID syn-
drome. A series of biennial international meetings on
fragile X syndrome and XLID, beginning in 1983, involved
about 100 investigators and provided a sense of unity and
progress to the field. Papers and abstracts from these meet-
ings and from other research were published (usually bien-
nially) as conference reports, special issues or updates on
XLID from 1984 to 2008.6–16
The focus of this review will be the discovery process
rather than the details of the clinical or molecular findings
in the individual XLID entities. Readers are referred to the
recently updated excellent review of the fragile X in OMIM
(MIM 300624) and OMIM entries on other XLID disorders
as detailed in Tables S1 and S2. Other reviews of different
aspects of XLID include the periodic XLID updates from
1984 to 2008, an Atlas of XLID Syndromes,1 and a number
of commentaries by individual investigators.3,17–22XLID before Fragile X
The prelude to the current cytogenetic and molecular era
covered a century (1868–1968). It encompassed descrip-
tions of a number of clinically defined entities (Pelizaeus-
Merzbacher disease [MIM 312080], Duchenne muscular
dystrophy [MIM 310200], incontinentia pigmenti [MIM
308300], Goltz focal dermal hypoplasia [MIM 305600],
Lenz microphthalmia syndrome [MIM 309800]), inborn
errors of metabolism (Hunter syndrome [MIM 309900],
Lowe syndrome [MIM 309000], Lesch-Nyhan syndrome
[MIM 300322]), and large pedigrees in which ID segregated
with an X-linked pattern.23–28 During the same period, the
excess of males among persons with ID was observed in3 Gregor Mendel Circle, Greenwood, SC 29646, USA
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Figure 1. Genes with Identified Mutations that Cause Syndromal XLID with Chromosomal Band Locationcensus surveys and other population studies.29–31 The
magnitude of the male excess, varied from study to study
but averaged about 30 percent and was found in nearly
all studies.
These two observations—the excess of males among
persons with ID and clinical syndromes or families with
ID that segregated with an X-linked pattern—provided
compelling evidence that genes on the X chromosome
were important contributors to the overall causation of
ID and, hence, of individual, familial, and societal signifi-
cance. By virtue of having but a single X chromosome,
the male’s genome was uniquely vulnerable and that
vulnerability extended to brain development and function
as well as to other systems.
Further insights during this early period of time were
that XLID comprised syndromal entities (ID plus somatic,
metabolic, or neuromuscular manifestations) and nonsyn-
dromal entities (ID alone or with inconsistent abnormali-
ties). It also became clear that some females in XLID
pedigrees had intellectual limitations, albeit with neither
the consistency nor the severity of males. Technological
limitations (lack of tools for linkage analysis and gene580 The American Journal of Human Genetics 90, 579–590, April 6, 2isolation) precluded a more precise genetic characteriza-
tion of XLID disorders and delayed the clinical delineation.
The Setting of the Initial Observation of the Marker X
In 1966, when a one-year-old boy and his brother were
referred to the Yale chromosome laboratory for study
because of delayed development, medical cytogenetics
was in a period of transition. The major trisomies as well
as translocations and large deletions had been defined by
nonspecific orcein or Giemsa staining. Prenatal cytoge-
netic diagnosis had begun and in order to provide more
predictive developmental information to families, there
was a need for both better, less biased clinical information
about X and Y aneuploidy and the several types of smaller
variations in the short arms of the acrocentric chromo-
somes and variant heterochromatic regions on 1, 9, 16,
and Y. The Yale laboratory had selected a minimal media
(199) for both routine diagnostic studies and for a year-
long study of 4,500 consecutive cord blood and 500
maternal samples. Special attention was given to breaks,
gaps, and chromosome variants in the year-long study.
The study also sought to identify cytogenetic markers012
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Figure 2. Location of Genes with Mutations that Cause Nonsyn-
dromal XLID
Twenty-two genes shown on the left of the chromosome with
solid arrows cause nonsyndromal XLID only. Numbers in paren-
theses adjacent to the gene symbols are assigned MRX numbers.
Seventeen genes shown on the right of the chromosome with
open arrows cause both syndromal and nonsyndromal XLID.
Table 1. Nonsyndromal XLID families (MRX1 – MRX95) with
linkage or gene identificationa
1 IQSEC2 33 ARX 65 Xp11.3-q21.33
2 Xp22.1-p22.3 34 del IL1RAPL1 66 Xq21.33-q23
3 HCFC1 35 Xq21.3-q26 67 Xq13.1-q21.31
4 Xp11.22-q21.31 36 ARX 68 ACSL4
5 Xp21.1-q21.3 37 Xp22.31-p22.32 69 Xp11.21-q22.1
6 Xq27 38 ARX 70 Xq23-q25
7 Xp11.23-q12 39 Xp11 71 Xq24-q27.1
8 DLG3 40 Xq21 72 RAB39B
9 FTSJ1 41 GDI1 73 Xp22-p21
10 Xp11.4-p21.3 42 Xp11.3-q13.1; Xq26 74 Xp11.3-p11.4
11 Xp11.22-p21.3 43 ARX 75 Xq24-q26
12 THOC2 44 FTSJ1 76 ARX
13 Xp22.3-q22 45 ZNF81 77 Xq12-q21.33
14 Xp21.2-q13 46 ARHGEF6 78 Xp11.4-p11.23
15 Xp22.1-q12 47 PAK3 79 MECP2
16 MECP2 48 GDI1 80 Xq22-q24
17 dup HUWE1 49 CLCN4 81 Xp11.2-q12
18 IQSEC2 50 Xp11.3-p11.21 82 Xq24-q25
19 RPSKA3 51 Xp11.23-p11.3 83 Not published
20 Xp21.1-q23 52 Xp11.21-q21.32 84 Xp11.3-q22.3
21 IL1RAPL1 53 Xq22.2-q26 85 Xp21.3-p21.1
22 Xp21.1-q21.31 54 ARX 86 Not published
23 Xq23-q24 55 PQBP1 87 ARX
24 Xp22.2-p22.3 56 Xp21.1-p11.21 88 AGTR2
25 Xq27.3 57 Xq24-q25 89 ZNF41
26 Xp11.4-q23 58 TM4SF2 90 DLG3
27 Xq24-q27.1 59 AP1S2 91 ZDHHC15
28 Xq27.3-qter 60 OPHN1 92 ZNF674
29 ARX 61 Xq13.1-q25 93 BRWD3
30 PAK3 62 UPF3B 94 GRIA3
31 dup HUWE1 63 ACSL4 95 MAGT1/OSTb
32 ARX 64 dup MECP2
aMutations inNLGN4, CDKL5, KDM5C, FGD1, SLC16A2, ATRX, AFF2 and SLC6A8
have been found in other families with nonsyndromal XLID.that might correlate directly with clinical conditions.32
Thus, the initial observation that the two brothers referred
to the laboratory because of ID had a consistent chromatid
break or constriction in the distal long arm of a large C
group chromosome was very pertinent to the research
goals of the laboratory. Further study revealed that their
normal mother and two maternal relatives with ID (an
uncle and great uncle of the boys) had the same marker
X chromosome.
The pedigree was, of course, consistent with X-linked ID.
Studies with H3 thymidine showed that the late repli-
cating, large C group chromosome was the same as the
chromosome with the apparent breaks and secondaryThe Amconstrictions. The data led to the conclusion that ‘‘either
the secondary constriction itself or a closely linked
recessive gene may account for the pattern of X-linked
inheritance’’.4 This was, in fact, probably the first precise
localization of a gene associated with human disease. The
fragile X locus was subsequently defined as an uncoiled
region (secondary constriction) by electron microscopy.33
Studies from a number of laboratories would provide a
more precise confirmation and molecular characterizationerican Journal of Human Genetics 90, 579–590, April 6, 2012 581
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Figure 3. Approximate Linkage Limits for XLID Syndromes for which the Genes Have Not Been Identifiedof the location in the ensuing decade34–36 and identifica-
tion of the gene itself in 1991.37–40
In addition, the juxtaposition and timing of the family
study and the population survey permitted us to look for
the marker X in 5,000 individuals and over 30,000 cells
and to conclude tentatively that it was not a common
marker or variant because not even one marker X cell
was observed. Another family with a similar chromosomal
appearance at distal 16q was also ascertained in this same
interval. This was inherited in an autosomal-dominant
manner and not associated with a disease. We were, there-
fore, able to make the preliminary conclusion that such
markers did not necessarily indicate disease but that the
marker X was a significant clinical marker for a Mendelian
disease and hence a new and useful tool.
Observations in the 1970s and 1980s
More complex and folic-acid-enriched media become
popular during the 1970s and presumably made detection
of the fragile X increasingly difficult. Most early studies
gave variable results and were not published. The initial
report was confirmed by Giraud et al.34 and Harvey
et al.35 These articles and the report by Sutherland36 estab-
lished that folic acid in the culture media prevented the
expression and detection of the fragile X.
During the 1980s it became clear that a majority of XLID
families did not have fragile X, and the identification and
study of large non-fragile X XLID families with linkage582 The American Journal of Human Genetics 90, 579–590, April 6, 2analysis began in earnest. Large scale studies began across
the globe at this time. The results summarized in Table 1,
Tables S1 and S2, and Figures 1, 2, and 3 are, therefore,
based on about 20 years of clinical and molecular studies.
Methodologies Quicken the Pace of Gene Discovery
Besides the cytogenetic methods used in the diagnosing
and confirmation of fragile X, a number of strategies
have been utilized to identify XLID genes (Table S1 and
Figures 1 and 2). Prior to 1990, these were limited to the
pursuit of genes in cases where the gene products (enzymes
in all cases: HPRT [MIM 308000], PGK1 [MIM 311800],
OTC [MIM 311250] , and PDHA1 [MIM 300582]) were
known, the molecular pathway was known (PLP [MIM
300401]) or a chromosome aberration had localized the
candidate region (DMD [MIM 300377]). Over the next
decade and a half, exploitation of chromosome rearrange-
ments and linkage coupled with candidate gene testing
dominated the field. In the past several years, X chromo-
some sequencing, microarrays (expression and genomic),
and exploration of molecular pathways have added to
the range of technologies available for XLID gene identifi-
cation. Five of the first seven gene identifications were
accomplished with a combination of known metabolic
pathways and tissue culture studies in families with inborn
errors of metabolism (Figure 4). The first identification,
Lesch-Nyhan syndrome due to mutations in HPRT, was re-
ported in 198341 and the most recent was the creatine012
Figure 4. The Year and Methodology Used to Identify Genes Associated with XLID
The following abbreviations are used: Exp-Arr ¼ expression microarray. MCGH ¼ genomic microarray. X-seq ¼ gene sequencing.
Mol-Fu ¼ follow up of a known molecular pathway. L-can ¼ candidate gene testing within a linkage interval. Chr-rea ¼ positional
cloning based on a chromosome rearrangement. Met-Fu ¼ follow up of a known metabolic pathway.transporter syndrome (MIM 300352) due to mutations in
SLC6A8 [MIM 300036].42 Mutations in seven genes were
identified by this methodology.
Two workhorse approaches have been responsible for
the great majority of subsequent gene identifications.
The first of these, based on the ascertainment of a patient
with both ID and a chromosomal rearrangement involving
the X chromosome, was used successfully in identifying
the gene associated with Duchenne muscular dystrophy
in 1987. A total of 31 genes (Table S1 and Figure 4) had
been identified by the middle of 2011 with this approach.
The second and most productive ‘‘workhorse’’ approach,
linkage study of XLID families followed by molecular
analysis of appropriate candidate genes, was employed
initially by a number of investigators in detecting and
characterizing FMR1 (MIM 309550). Subsequently, its use
has resulted in the identification of 43 mutant X genes.
With increasing ease of sequencing, the pace of gene iden-
tification by this route accelerated after 2003, as shown in
Table S1 and Figure 4.
The availability of brute force sequencing capability after
completion of the Human Genome Project has brought an
additional effective method of gene identification, and 21The Amhave been reported since 2006 (Table S1 and Figure 4).
Whether sequencing of large series of sporadic males,
male siblings, or families with clear XLID will prove to be
the most effective use of this resource remains to be deter-
mined. The selection of pedigree-based subjects for
sequencing, however, has the advantage that segregation
of gene alterations can be tested. Since this approach often
permits a relatively straight-forward path to gene identifi-
cation, continued collection of both clinical data and
blood samples remains important. Exploitation of a specific
molecular finding has accounted for four gene identifica-
tions (FANCB [MIM 300515], PORCN [MIM 300651],
SMC1A/SM1L1 [MIM 300040], NDUFA1 [MIM 300078]).
Two other new technologies, expression array and array-
comparative genomic hybridization have, surprisingly,
been applied successfully in only two and one instance,
respectively. Expression array was used in combination
with two other methods to discover the role of GRIA3
(MIM 305915) and PTCHD1 (MIM 300828) in ID. Array-
CGH was used in the isolation of the mutant gene in one
nonsyndromal family (HUWE1 [MIM 300697]).43 Many
potentially valuable combinations of array technologies
for screening followed with brute force sequencing canerican Journal of Human Genetics 90, 579–590, April 6, 2012 583
Wagenstaller et al.54, Horn et al.50
Gijsbers et al.49
22.3
22.2
22.1
Whibley et al.55
F t l 44
21.3
21.2
21.1
11.4
Froyen et al.45
royen e  a .
Bedeschi et al.48
11
12
11.3
11.1
11.23
11.22
11.21
Koolen et al.46
13
21.1
21.2
21 3
Mimault et al.51, Woodward et al.56
Koolen et al.46
23
.
22.1
22.2
22.3
Koolen et al.46
S l t
25
26
27
24
o omon e  al.53
Van Esch et al.47, Friez et al.43
Rio et al.52
28
Figure 5. Location of Segmental Duplications Associated with
Syndromal or Nonsyndromal XLID43–56be envisioned. Detection of a consistent up or downregula-
tion or other abnormality in two or more XLID family
members can certainly be envisioned as a fruitful approach
to the selection of subjects for partial or complete X
sequencing. Two or more approaches were used in combi-
nation in six instances among the 102 gene identifications
shown in Table S1 and Figure 1 (FMR1, MID1 [MIM
602148], SOX3 [MIM 313430], HUWE1, CASK [MIM
300172], and GRIA3). The application of CGH and related
methods in conjunction with a variety of molecular
technologies has increasingly been used to detect du-
plications and deletions of genes associated with XLID
(Figure 5).1,43–56
In spite of the identification of mutations in 102 genes
that result in XLID, the fragile X syndrome continues to
be by far the most frequent XLID syndrome. Whether
the gradual but continuous expansion of the number of
triplet repeats in the large bank of premutation carriers,
which vary from 1/113 in Israel to 1/313–382 in the United
States) plays a role in maintaining its relatively high gene
frequency is unknown.57
Lumping, Splitting, and Reclassification Based on
Gene Discovery: A Model for Future Research
Given the variability and imprecision with which clinical
evaluations are carried out, it is inevitable that some indi-
viduals with X-linked ID will be incorrectly included in
existing diagnostic categories, whereas others will be incor-584 The American Journal of Human Genetics 90, 579–590, April 6, 2rectly excluded. The extent to which individuals and
families can be evaluated is dependent on the setting,
access to historical information, availability and ages of
affected and nonaffected family members, and the ex-
perience and expertise of the observers. Differences in
phenotype can result frommutations in different domains
of a gene and by contributions from the balance of the
genome. The identification of mutations in many genes
associated with XLID has provided the opportunity to
compensate for some of these variables, resulting in the
lumping of entities previously considered to be separate
and the splitting of other entities previously considered
the same. In addition, the phenotypic limits of some
XLID entities were established with some degree of
objectivity.
Several XLID entities have been most instructive. Dis-
covery that mutations in ATRX (MIM 300032) (Xq21.1)
cause alpha-thalassemia ID allowed testing of large
number of males with hypotonic facies, ID, and other
features.58–60 Currently, as shown in Table S1, four other
named XLID syndromes (Carpenter-Waziri, Holmes-
Gang, XLID-Hypotonia-Arch Fingerprints, and Chudley-
Lowry syndromes [MIM 309580]) have been found to be
allelic variants of alpha-thalassemia ID as have certain
families with spastic paraplegia and nonsyndromal
XLID.1,61–65 One family clinically diagnosed as Juberg-
Marsidi syndrome was found to have an ATRX muta-
tion.66,67 This is now known to be based on misdiagnosis
of Juberg-Marsidi syndrome (MIM 300612); indeed, the
original family with this syndrome has a mutation in
HUWE1 at Xp11.22 (Friez et al., 2011, 15th International
Workshop on Fragile X and Other Early-Onset Cognitive
Disorders). One family clinically diagnosed as Smith-
Fineman-Myers syndrome was also found to harbor an
ATRX mutation, but the gene has not been analyzed in
the original family.68–70 A clinically similar condition,
Coffin-Lowry syndrome (MIM 303600), was found to be
separate from alpha-thalassemia ID and due to mutations
in RPS6KA3 (MIM 300075), which encodes a serine-threo-
nine kinase.71
Kalscheuer et al.72 found mutations in PQBP1 (MIM
300463) (Xp11.2) in two named XLID syndromes – Suther-
land-Haan syndrome (MIM 309470) and Hamel cerebropa-
latocardiac syndrome (MIM 309500)—in MRX55 and
two other families with microcephaly and other findings.
Lenski et al.,73 Stevenson et al.,74 and Lubs et al.75 added
Renpenning, Porteous, and Golabi-Ito-Hall syndromes to
the list of XLID syndromes caused by mutations in
PQBP1.73–75 The six phenotypes now attributed to muta-
tions in PQBP1 are now summarized in the allelic variants
of OMIM 300463. As with the ATRX phenotypes, a wide
variety of phenotypic expressions result from different
mutations in PQBP1 and we remain challenged to better
understand the molecular and developmental mecha-
nisms leading to these differences.
Mutations in ARX (MIM 300382) (Xp22.2) were also
found to be an important cause of XLID encompassing012
multiple phenotypes. Alterations, most commonly a 24 bp
expansion of a polyalanine tract, were found in a number
of families with nonsyndromal XLID (MRX29, 32, 33, 36,
38, 43, 54, and 76), an X-linked dystonia (Partington
syndrome [MIM 309510]), X-linked infantile spasms
(MIM 308350) (West syndrome), X-linked lissencephaly
with abnormal genitalia (MIM 300215), hydranencephaly
and abnormal genitalia (MIM 300215), and Proud
syndrome (MIM 300215).76–83
Perhaps the most prominent example of syndrome split-
ting is FG syndrome (MIM 305450). This syndrome,
initially described in 1974 by Opitz and Kaveggia,84 is
manifest by macrocephaly (or relative macrocephaly),
downslanting palpebral fissures, imperforate anus or
severe constipation, broad and flat thumbs and great
toes, hypotonia, and ID. In the ensuing years, the manifes-
tations attributed to FG syndrome have become protean,
but none was pathognomonic or required for the
diagnosis.85–88 As a result, a number of different localiza-
tions on the X chromosome were proposed for FG
syndrome.89–95
In 2007, Risheg et al.96 found a recurring mutation,
c.2881C>T (p.Arg961Trp), in MED12 (MIM 300188) in
six families with the FG phenotype, including the original
family reported by Opitz and Kaveggia.84 In addition to the
above noted manifestations, two other findings, small ears
and friendly behavior, were consistently noted.
Although most individuals who have carried the FG
diagnosis have one or more findings that overlap with
those in FG syndrome, they do not have MED12 muta-
tions.97,98 Some have been found to have mutations in
other X-linked genes (FMR1, FLNA [MIM 300017], ATRX,
CASK, and MECP2 [MIM 300005]), whereas others have
duplications or deletions of the autosomes.97 So great is
the currently existing heterogeneity within FG syndrome
that the vast majority of individuals so designated should
best be considered to have ID of undetermined cause.
In a number of instances, certain gene mutations have
been associated with nonsyndromal XLID, whereas other
mutations within the same genes have caused syndromal
XLID. Mutations in 17 genes that may cause either type
of XLID, depending on the mutation, have been identified
(Figure 2). In some cases (e.g., those with OPHN1 [MIM
300127] and ARX mutations) re-examination has found
syndromal manifestations in families previously consid-
ered to have nonsyndromal XLID.79,99,100
The frequency with which the process of lumping and
splitting in this limited field of investigation has occurred
has been extremely instructive to both clinical and molec-
ular investigators. Moreover, the process of reclassifying
and refining the XLID syndromes in light of the gene iden-
tificationsmay be one of themost important contributions
by medical genetics to clinical medicine. The underlying
mechanisms or pathways by which mutations in different
genes result in similar phenotypes and different mutations
in a single gene result in disparate phenotypes, however,
remain to be fully elucidated.The AmImproved Understanding of Disease Mechanisms
in XLID Disorders
Analysis of the presently known 102 genes associated with
XLID lends some insight into the numerous molecular
functions in which disruption can lead to cognitive
impairment and impaired brain development.17 Three
major functions are almost equally represented in proteins
encoded by this panel of 102 genes: 22% are involved in
regulation of transcription, 19% in signal transduction,
and 15% in metabolism. Additionally, 15% are compo-
nents of membrane-associated functions. The remainder
are equally distributed (~3%–5%) in seven other cellular
functions: cytoskeleton, RNA processing, DNA metabo-
lism, protein synthesis, ubiquitinization, cell cycle, and
cell adhesion. Regarding their localization within a cell,
the proteins encoded by genes associated with XLID are
almost equally distributed among the four major subcel-
lular fractions: 30% in the nucleus, 28% in the cytoplasm,
18% in the membranes, and 16% in cellular organelles.17
The XLID disorders offer many opportunities for under-
standing the functions of specific genes and their interac-
tions with other genes in producing disease. Studies
involving control of gene expression will necessarily be
especially complex. These have just begun, in part because
of their complexity and the rapid development of new tech-
niques. Only recently, for example, has a preliminary ex-
pressionmicroarray analysis been carried out in twoaffected
fragile X males.101 The study identified over 90 genes with
a greater than 1.5-fold change in expression. Overrepre-
sented genes were involved in signaling (both under-
and overexpression), morphogenesis (underexpression),
and neurodevelopment and function (overexpression).
Although not addressed in this study, the possibility that
a hallmark finding in the fragile X syndrome, enlargement
of the testes, might result from altered control of tubular
growth by a specific target gene is intriguing. One of the
90 genes identified, NUT (nuclear protein in testis [MIM
608963]), which is normally only expressed in the testis,
should be a candidate gene in future studies because the
BRDA-NUT fusion oncogenes are critical growth promoters
in certain aggressive carcinomas.102 Alternatively, a more
general growth-controlling gene might also explain the
prognathism, macrocephaly and large hands which occur
in some individuals with the fragile X syndrome.
Studies directed at understanding the mechanisms
underlying recurring clinical problems in XLID disorders
such as short stature, microcephaly or macrocephaly,
autistic behavior, and structural CNS abnormalities103
are also particularly appealing because they provide an
opportunity both to simultaneously understand critical
pathways, such as in dendrite development and the devel-
opment of XLID structural abnormalities, gene expression,
and phenotype. The association of autism spectrum dis-
order with mutations in at least eight of the 102 genes
listed in Table S1 is of particular current interest. This has
been reported most frequently in the fragile X syndrome
and Rett syndrome but also in disorders resulting fromerican Journal of Human Genetics 90, 579–590, April 6, 2012 585
mutations in NLGN3 (MIM 300336), NLGN4 (MIM
300427), RPL10 (MIM 312173), RAB39B (MIM 300774),
PTCHD1, andMED12. These genes, however, affect a wide
range of functions (Table S1), and the cause of the clinical
overlap is not clear. In nonsyndromal XLID, for example,
mutations have been identified in five genes involved in
the RhoGTPase cycle that affect dendritic outgrowth
(OPHN1, PAK3 [MIM 300142], ARHGEF6 [MIM 300267],
TM4SF2 [MIM 300096], and GDI1 [MIM 300104]) and are
central to the development of the nonsyndromal pheno-
type.1,17,104
The limited imaging and direct studies of macrocephaly,
microcephaly, and cerebellar hypoplasia have recently
been summarized,104 but more extensive application of
anatomical and functional brain imaging and spectros-
copy techniques that can identify variations in specific
brain regions for each disorder, in conjunction with both
clinical observations and psychometric studies, is critically
needed.
Detection of Possible Advantageous Cognitive
and Behavioral Genes
The identification of 102 X-linked genes affecting intelli-
gence has raised the probability that X chromosomal genes
(including XLID genes) might play a particularly impor-
tant role in brain structure and function as well as a specific
role in intelligence and certain cognitive abilities. Clearly,
as discussed at the beginning of this paper, the research
planned and carried out to identify XLID genes and
syndromes over the last several decades might account
for part or even all of this relative excess compared to auto-
somal loci. A number of papers, however, have addressed
the issue of active selection during evolution for X chro-
mosomal localization of important brain and cognitive
genes.2,105,106 The finding that human and mouse X chro-
mosome genes are hyperexpressed in the CNS compared to
autosomal genes provided additional important confirma-
tory data for the hypothesis of positive evolutionary selec-
tion.107 These studies showed not only that there was a
doubling of X chromosome expression (compared to auto-
somes) early in development (leading to dosage compensa-
tion), but overexpression in human CNS tissue and in
mouse CNS tissue increased by 2.83 and 2.53, respec-
tively, compared to expression in somatic tissues. These
observations also support the general idea that X genes
are particularly important for brain development and
function. Mutations significantly improving intellectual,
creative, perceptive, and leadership qualities would be
fully expressed in males and reasonably could have been
positively selected for in a relatively short period of time
in contrast to the negative selection for XLID muta-
tions.108–112 In essence, the XY males may have been the
experimental animal and the XX female, the storage
facility for both advantageous and deleterious mutations.
Medical investigations generally focus on adverse effects
and no organized searches for X-linked pedigrees with
particularly high intellectual or special cognitive talents586 The American Journal of Human Genetics 90, 579–590, April 6, 2have been reported. Thus, the same approach that has
been effective in identifyingXLID syndrome genes, investi-
gating families with an X-linked pattern of intellectual
outliers, might also prove rewarding for studies at the other
end of the intellectual spectrum. What if we selected for
families with an X-linked pattern of high intellectual
accomplishment; special talents in art or music; unique
types of cognitive behavior involving memory, problem
solving, or, indeed, any type of special intellectual accom-
plishment such as Nobel awards in Economics or Physics?
Such families will certainly be uncommon but so are most
XLID disorders. Yet families might be identified if academi-
cians asked the pertinent family history questions during
lunch with colleagues, a dedicated, interactive home page
was available, or notices were placed in journals asking for
information about possible families. The same group of
laboratories that contributed to the data in Table S1 would
be logical sources for referral andmolecular studies because
the necessary cognitive and molecular studies are already
in place. A positive result might be even bemore important
to society than XLID disease description and provide
important insight into human evolution.
Although there is a wide array of pertinent cognitive
tests, these were not designed to detect specific familial
talents. The coapplication of a pedigree analysis with perti-
nent laboratory tests should provide sufficiently precise
initial diagnosis of the affected to carry out linkage and
array or other screening tests successfully. One family
with four to five outstanding individuals over several
generations could provide sufficient data to warrant testing
other families (or even other species) and to begin an iden-
tification process similar to that described in this paper
that has proven successful for XLID. Imagine the prospects
for investigating specific gene-environmental interactions
during learning and development!
Why, other than not having looked seriously, have
we not stumbled upon such families? Perhaps we have.
In the Inaugural Book of the new National Museum
of the American Indian, Native Universe, Voices of Indian
America,113 in which tribal leaders, writers, scholars, and
story tellers describe Indian traditions and heritages, the
following is recounted:
‘‘Story tells us that a group split from the Lenni Lenape,
perhaps a thousand years ago or more. The people then
settled on the Eastern Shore of the Chesapeake, and were
one and the same as the Nanticoke. Then, for some reason,
the first Tayac, Uttapoingassenum, led his people to the
other side of the bay. Upon their arrival, they encountered
peoples who had been living on the land for more than
8,000 years, according to various archeological estimates.
For thirteen generations prior to English settlement, as
told to Jesuit andMoravianmissionaries, the Tayac’s inher-
itance passed from brother to brother and then to the
sister’s sons. Each led the people until his death.’’
The possibility that the Nanticoke had intuitively recog-
nized and employed a quality of leadership that followed
an X-linked pattern of inheritance is intriguing to consider.012
Although much progress has been made during the past
four decades, the clinical and molecular delineation of
XLID is far from complete. Perhaps little more than half
of the genes in which mutations will result in XLID have
been identified. The molecular pathways are incompletely
understood, the mechanisms by which brain structure and
function are deranged have not been identified, and with
few exceptions the neurobehavioral profiles and natural
history of the XLID entities have received insufficient
attention. These deficiencies notwithstanding, consider-
able benefits have been gained for individuals with XLID
and their families. Specific molecular tests, including mul-
tigene panels, are now available to more efficiently reach
a diagnosis. Carrier testing, donor eggs, prenatal diagnosis,
and preimplantation genetic testing may be used to
prevent recurrence when a specific genemutation is found.
Through these measures, reproductive confidence may be
restored for families in which XLID has occurred.114Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cell.com/AJHG/.Web Resources
The URLs for data presented herein are as follows:
Greenwood Genetic Center, XLID Update, http://www.ggc.org/
research/molecular-studies/xlid.html
Online Mendelian Inheritance in Man (OMIM), http://www.
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